36 weeks (1) , together with the days of invasive and noninvasive mechanical ventilation and oxygen treatment. Sepsis was defined by presence of both clinical and laboratory findings (temperature instability, metabolic acidosis, cardiorespiratory instability, hyperglycemia, capillary refill time .2 s, c-reactive protein, IL-6, total white cell count, and immature to total neutrophil ratio). Some cases were confirmed by pathogen detection from blood or cerebrospinal fluid. Chorioamnionitis was confirmed by placental histology (50%) or maternal/fetal signs of infection at birth.
Biomarker analysis. Serial plasma samples generated from a whole-blood ethylenediaminetetraacetic acid specimen obtained in the first week of life (Days 0-4, n = 16; Days 5-7, n = 16) and at Day 28 (n = 14) were subjected to proteomic screening (SOMAscan; SomaLogic). Protein binding to 1,129 individual high-affinity molecules was quantified by custom Agilent hybridization array (2, 3) with high reproducibility even in low-amount samples smaller than 100 ml. Row Z-Score Statistical analysis. Forty-seven samples passed the SOMAscan quality control. Outliers were identified by principal component analysis (prcomp function, R framework, and log-transformed data). First, to subtract confounding effects by considering low sample number, we applied L1-regularized regression (Lasso) in each expression profile, using the critical clinical variables presented in Table 1 , excluding disease outcome. Second, to identify diseaserelated biomarkers, we fitted a generalized additive model including disease information (BPD 0 vs. BPD 1, 2, and 3) as binary variables, time points as spline effects, and patients as random effects. Benjamini-Hochberg correction for multiple testing was applied. Gene Set Enrichment Analysis (P , 0.1) (4) was used with functional annotations from Gene Ontology. Logistic regression model with forward model selection identified the minimal protein set best describing different BPD levels in the significantly associated proteins. Akaike information criterion quantified the quality of each model, thereby simultaneously accounting for predictive power and model complexity (5) . Poisson regression was used to model the count variables "days of oxygen supplementation" and "days of mechanical ventilation" under the consideration of the clinical confounding variables (Table 1) .
Results
After correction for clinical confounding variables (Table 1) , 12 proteins were significantly regulated in preterm infants developing BPD ( Figure 1A ; P , 0.1; false discovery rate, 0.053-0.096), reflecting the Gene Ontology categories identified by functional enrichment analysis (e.g., immune function, defense response, extracellular matrix, cellular proliferation, cellular migration, and organ development).
Increased detection levels for SIGLEC-14 and BCAM in combination with decreased levels for ANGPTL3 in the first week of life were found to describe the outcome variable BPD with high specificity and sensitivity with model selection showing separation of disease groups ( Figures 1B and 1C) . Analysis using the count variable "oxygen supplementation" and "ventilator support" confirmed the results. Protein levels remained stable at Day 28 of life. Validation of the findings succeeded in a second, independent cohort, using individual logistic regression ( Figure 1D ). Pulmonary expression of the proteins and their characteristic regulation was demonstrated in lung tissue sections from patients with BPD ( Figure 1E ).
Discussion
Our study establishes a validated set of proteins identifying BPD early after birth, indicating key processes of disease development by the use of proteomic screening in preterm infants. Both unbiased screening as well as validation experiments significantly add to previous studies using single markers lacking disease specificity and validation (6) .
Of the significantly regulated proteins closely reflecting BPD pathophysiology, early plasma levels of SIGLEC-14, BCAM, and ANGPTL3 showed high sensitivity and specificity for BPD, exceeding the prognostic value of clinical variables currently used for risk stratification (7) . Expressed on granulocytes and monocytes, SIGLEC-14 is attributed to invasive infections in newborns (8) and lung disease in adults (9) through pathogen-induced host immune suppression. BCAM, associated with impaired airway branching and lung structure development, and ANGPTL3, playing a role in endothelial development and survival, likely indicate structuralterm effects. The potential of the proteins to risk-stratify affected infants with BPD into respective disease-subtypes as well as their value as treatment targets need to be exploited further. The potential of the plasma proteins to serve as BPD biomarkers is supported by proving their pulmonary expression and demonstrating their stable expression levels in the later disease course. Limitations of our study include the patient number (which we, however, consider adequate for a pilot study) and the fact that despite the prospective study design, patients cannot be considered randomly assigned to the disease groups. To overcome the limitations of disease grading, all critical findings from the study were confirmed by the use of the count variables "duration of mechanical ventilation" and "duration of oxygen supplementation" and the investigation of two independent cohorts. Despite significant differences between the two cohorts with respect to some clinical variables, the confirmation of the biomarkers emphasizes the robustness of the results.
In summary, our study is a first step toward an early diagnostic tool allowing for timely decision-making, disease monitoring, and development of personalized treatment strategies in BPD, as recommended (10) . n Author disclosures are available with the text of this letter at www.atsjournals.org.
Gastric Banding Surgery versus Continuous Positive Airway Pressure for Obstructive Sleep Apnea: A Randomized Controlled Trial
To the Editor:
We performed a randomized trial of continuous positive airway pressure (CPAP) versus laparoscopic gastric banding (LGB) for patients with severe obstructive sleep apnea (OSA), hypothesizing that residual disease (effective apnea-hypopnea index [AHI]) (1-3) and Epworth Sleepiness Scale (ESS) scores would be significantly lower with LGB compared with CPAP at 9 and 18 months. Approval was obtained from the institutional review boards at Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. The protocol was registered at clinicaltrials.gov (NCT01187771). All participants gave written informed consent.
The inclusion criteria were age 18-65 years, body mass index (BMI) 35-45 kg/m 2 , severe OSA (AHI > 30 events/h [level 1 study] or AHI > 20 events/h [level 3 study]), and at least one OSA symptom. The exclusion criteria were prior CPAP or bariatric surgery, hypoventilation syndrome, increased perioperative risk, drowsy driving, non-English fluency, or any unstable medical condition. Suitability for both treatments, as well as the equipoise of each patient, was established by a sleep specialist and bariatrician before consent was obtained.
Patients underwent attended polysomnography using the Compumedics E-Series at baseline, 9 months, and 18 months.
Randomization was stratified by recruitment clinic, baseline BMI (35-40 or 40-45 kg/m 2 ), and sex. Sequences had block sizes of two and four, with a 50% chance of choosing either one.
Initiation and management of OSA care once treatment was assigned were performed by the managing clinician as per usual care, except that patients undergoing LGB were provided auto-CPAP (REMstar Auto M Series; Philips Respironics) during the perioperative period to minimize OSA complications. The effective AHI was calculated as (x 3 AHI on-CPAP ) 1 [(1 2 x) 3 AHI off-CPAP ], where x is (CPAP adherence)/(habitual sleep duration) (3). Adherence and AHI on-CPAP were downloaded from the device and averaged across the previous 30 days. AHI off-CPAP was calculated from polysomnography data obtained at 9 or 18 months.
We performed an a priori power analysis to determine the difference in effective AHI between arms, indicating a sample size of 80. With the support of our Data Safety Monitoring Board and approval from the NHLBI, we performed a second power calculation while the study was underway. We assumed a mean baseline AHI [mean 6 SD] of 50 6 10 events/h. In the CPAP group, we assumed a mean CPAP adherence of 4 h/night and usual sleep duration of 8 h/night, resulting in an effective AHI of 25 events/h. In the LGB group, based on a published meta-analysis, we anticipated a 31% reduction in AHI, resulting in an effective AHI of 35 events/h (4). Under these assumptions, we would have .90% power to detect a benefit of LGB with a sample size of 50.
We made between-arm comparisons using linear models with prespecified adjustments for randomization stratification factors. Within-arm comparisons were based on the difference between baseline and end-trial data, using one-sample t tests or signed-rank tests. Tests were considered statistically significant when P , 0.05 (two-sided). Figure 1 shows that 49 patients were randomized. In the LGB group, 14/28 underwent LGB only (50%), 10 underwent CPAP only (36%), and four underwent neither (14%). In the CPAP group, 20/21 received CPAP only (95%), and one began CPAP followed by gastric bypass surgery (5%).
LGB was associated with a greater drop in BMI (Table 1 ). In intention-to-treat analyses, the effective AHI at 9 months was 29.5 6 23.4 and 20.0 6 25.3 events/h in the LGB and CPAP groups, respectively (P = 0.02). At 18 months, the effective AHI was 20.9 6 16.0 and 21.4 6 17.6 events/h (P = 0.89). Although there were significant improvements in ESS scores with both treatments, there were no significant differences between arms. Self-reported sleep durations were 7.4 6 1.4, 7.4 6 1.3, and 7.3 6 1.2 h/night at baseline, 9 months, and 18 months, respectively, in the surgery arm, and 8.5 6 1.8, 8.0 6 1.4, and 8.4 6 1.5 h/night, respectively, in the CPAP arm.
Analyses limited to patients who received their assigned treatment (n = 14 LGB; n = 20 CPAP) produced similar results, that is, a greater improvement in effective AHI with CPAP (18.6 6 25.3 vs. 28.2 6 15.7 at 9 mo, P = 0.02) and no difference in ESS scores (7.2 6 4.3 vs. 5.9 6 3.5 at 9 mo, P = 0.98). Changes in AHI varied linearly with changes in BMI, with a 3.3% (SEM, 1.5%) reduction in AHI for every 1% reduction in BMI and no difference in slope by treatment.
To our knowledge, this is the first randomized trial to compare bariatric surgery and CPAP as initial treatment for OSA. We found that the effective AHI at 9 months was significantly lower with CPAP, and there was no difference in daytime sleepiness between groups. Neither of these findings supported our hypotheses. The rate of OSA resolution with LGB was fairly low, in keeping with 
